Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Period	PE Ratio
2020-12-31	-11.37
2021-12-31	-11.11
2022-12-31	-10.19
2023-12-31	-13.97
2024-12-31	-2.32

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVB	$4.89	-2.98%	4.20M
3
4
5

Nuvation Bio Inc. Class A (NUVB) PE Ratio

PE Ratio Data

Get Nuvation Bio Inc. Class A Data in Excel

More NUVB Financial Data